Are High Doses of Prednisone Necessary for Treatment of Interstitial Lung Disease in Systemic Sclerosis?;¿Son necesarias las dosis elevadas de prednisona para el tratamiento de la neumopatía intersticial en la esclerosis sistémica?

Reumatologia Clinica

Volumn 8, Issue 2, 2012, Pages 58-62

  Pérez Campos, Dionisio ^a   Estévez Del Toro, Miguel ^a   Peña Casanovas, Aisa ^a   González Rojas, Pedro Pablo ^a   Morales Sánchez, Lisvenia ^a   Gutiérrez Rojas, Ángela Rosa ^a  

^a HOSPITAL CLINICOQUIRÚRGICO HERMANOS AMEIJEIRAS   (Cuba)

Author keywords

Cyclophosphamide; High and low doses of prednisone; Interstitial lung disease; Systemic sclerosis

Indexed keywords

CYCLOPHOSPHAMIDE; PREDNISONE;

ARTICLE; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; HUMAN; INTERSTITIAL LUNG DISEASE; LOW DRUG DOSE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WARRICK INDEX;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS; CYCLOPHOSPHAMIDE; CYSTITIS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; LUNG DISEASES, INTERSTITIAL; MALE; NAUSEA; PREDNISONE; PULSE THERAPY, DRUG; SCLERODERMA, SYSTEMIC; SINGLE-BLIND METHOD; TREATMENT OUTCOME; VOMITING;

EID: 84858446907     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2011.11.006     Document Type: Article

References (29)

1. Steen V.D., Conte C., Owens G.R., Medsger T.A. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994, 37:1283-1289.
2. Steen V. The lung in systemic sclerosis. J Clinical Rheumatol 2005, 11:40-46.
3. Ioannidis J.P.A., Vlachoyannopoulos P.G., Haldich A.B. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005, 118:2-10.
4. Silver R.M. Scleroderma clinical problems the lungs. Rheum Dis Clin North Am 1996, 22:825-840.
5. White B., Moore W.C., Wigley F.M., Xiao H.Q., Wise R.A. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000, 132:947-954.
6. White B. Interstitial lung disease in scleroderma. Rheum Dis Clin North Am 2003, 29:371-390.
7. Silver R.M., Warrick J.H., Kinsella M.B., Staudt L.S., Baumann M.H., Strange C. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993, 20:838-848.
8. Pakas I., Ioannidis J.P., Malagari K., Skopouli F.N., Moutsopoulos H.M., Vlachoyiannopoulos P.G. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002, 29:298-304.
9. Wanchu A., Suryanaryana B.S., Sharma S., Sharma A., Bambery P. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study. Int J Rheum Dis 2009, 12:239.
10. Preliminary criteria for the classification of systemic sclerosis. Arthritis Rheum 1980, 23:581-590. American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Subcommittee for Scleroderma Criteria.
11. Varga J. Prognosis and treatment of interstitial lung disease in systemic sclerosis: an update Bull NYU. Hosp Jt Dis 2008, 66:198-202.
12. LeRoy E.C., Black C.M., Fleischmajer R. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
13. Brennan P., Silman A., Black C. Reliability of skin involvement measures in scleroderma. Br J Rheumatol 1992, 31:457-460.
14. Guidelines for the measurement of respiratory function: recommendations of the British Thoracic Society and the Association of Respiratory Technicians and Physiologists. Resp Med. 1994;88:165-94.
15. Desai S.R., Eeraraghavan S., Hansell D.M., Nikolakopolou A., Goh N.S., Nicholson A.G., et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia. Radiology 2004, 232:560-567.
16. Warrick I., Bhalla M., Schabel S., Silver Rm High resolution computed tomography in early scleroderma lung disease. J Rheumatol 1991, 18:1520-1528.
17. Idiopathic pulmonary fibrosis: diagnosis and treatment international consensus statement. Am J Respir Crit Care Med 2000, 161:46-64. American Thoracic Society (ATS), and the European Respiratory Society (ERS).
18. Clements P.J., Roth M.D., Elashoff R., Tashkin D.P., Goldin J., Silver R.M., et al. Scleroderma lung study (SLS): Differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis 2007, 66:1641-1647.
19. Furst D.E., Clement P.J., Tashkin D., Elashoff R. Among a group of patients with dyspnea and alveolitis entering the scleroderma lung study (SLS), a surprising proportion have limited SSc (LSSc). Arthritis Rheum 2005, 52:592-600.
20. Hesselstrand R., Scheja A., Shen G.O., Wiik A., åkesson A. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology 2006, 42:534-540.
21. Rios G., Mayor A.M. Clinical and sociodemographic features of puerto ricans with systemic sclerosis. Ethn Dis 2010, 20:51-185.
22. Karen Au Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. Curr Rheumatol Rep 2009, 11:111-119.
23. Shah R.M., Jimenez S., Wechsler R. Significance of ground-glass opacity on HRCT in long-term follow-up of patients with systemic sclerosis. J Thorac Imaging 2007, 22:120-124.
24. Highland K.B., Garin M.C., Brown K.K. The spectrum of scleroderma lung disease. Semin Respir Crit Care Med 2007, 28:418-429.
25. Tashkin D.P., Elashoff R., Clements P.J. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006, 354:2655.
26. Simeón-Aznar C.P. Intravenous cyclophosphamide pulse therapy in the treatment of systemic sclerosis-related interstitial lung disease: a long term study. Open Respir Med J 2008, 2:39-45.
27. Hoyles R.K., Ellis R.W., Wellsbury J. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006, 54:3962.
28. Strange C., Bolster M.B., Roth M.D., Silver R.M., Theodore A., Goldin J., et al. Scleroderma lung study research group bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 2008, 177:91-98.
29. Andrade de Macedo P., Lobato Borges T., Christmann C., De Souza R.B. Cyclophosphamide: effective in the treatment of severe cutaneous involvement in systemic sclerosis. Bras J Rheumatol 2009, 49:265-275.